M&A / Deals Insilico Medicine, Takeda partner on AI-driven drug discovery Pharmaceutical Business ReviewUnder the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria.Read full story pharminent July 2, 2026 (Last updated: July 3, 2026) Pharmaceutical Business Review Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Selects Seven for PreCheck Pilot to Advance Drug ManufacturingNext: Roche’s KRAS drug tops its rivals in lung cancer trial Related Stories M&A / Deals AZ forges ever-closer ties with China’s CSPC Pharma pharminent July 2, 2026 M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal pharminent July 1, 2026 M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash pharminent June 29, 2026
